These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36497135)

  • 21. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 22. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
    Cheng F; Hansson VC; Georgolopoulos G; Mani K
    Oncotarget; 2023 Mar; 14():219-235. PubMed ID: 36944188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
    Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
    Front Immunol; 2022; 13():903461. PubMed ID: 35663977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The panoramic picture of pepsinogen gene family with pan-cancer.
    Shen S; Li H; Liu J; Sun L; Yuan Y
    Cancer Med; 2020 Dec; 9(23):9064-9080. PubMed ID: 33067881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
    PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance].
    Xue LY; Zou SM; Zheng S; Xie YQ; Wen P; Liu XY; Lin DM; Lü N
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):838-44. PubMed ID: 21223690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N
    BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-Cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many Cancers.
    Qureshi MA; Khan S; Tauheed MS; Syed SA; Ujjan ID; Lail A; Sharafat S
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3199-3209. PubMed ID: 33247676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of the novel omicron receptor AXL in cancers.
    Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kub5-Hera
    Motea EA; Fattah FJ; Xiao L; Girard L; Rommel A; Morales JC; Patidar P; Zhou Y; Porter A; Xie Y; Minna JD; Boothman DA
    Clin Cancer Res; 2018 Dec; 24(24):6459-6470. PubMed ID: 30108102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
    Liu P; Lin C; Liu L; Lu Z; Tu Z; Liu H
    J Biol Chem; 2022 Sep; 298(9):102354. PubMed ID: 35952757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
    J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m
    Du J; Fu J; Zhang W; Zhang L; Chen H; Cheng J; He T; Fu J
    Int J Oncol; 2023 Mar; 62(3):. PubMed ID: 36799191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-cancer analysis of G6PD carcinogenesis in human tumors.
    Liu B; Fu X; Du Y; Feng Z; Chen R; Liu X; Yu F; Zhou G; Ba Y
    Carcinogenesis; 2023 Aug; 44(6):525-534. PubMed ID: 37335542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
    J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.